Use of Cannabinoids for Spasticity and Pain Management in MS

被引：3

作者：

Chohan, Hardeep ^{[1
]}

Greenfield, Ariele L. ^{[1
]}

Yadav, Vijayshree ^{[2
]}

Graves, Jennifer ^{[1
]}

机构：

[1] Univ Calif San Francisco, Dept Neurol, 350 Parnassus Ave,304 A, San Francisco, CA 94117 USA

[2] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA

来源：

CURRENT TREATMENT OPTIONS IN NEUROLOGY | 2016年 / 18卷 / 01期

关键词：

Multiple sclerosis; Cannabinoids; Spasticity Pain; Tetrahydrocannabinol; Cannabidiol; GUIDELINE DEVELOPMENT SUBCOMMITTEE; MULTIPLE-SCLEROSIS; AMERICAN ACADEMY; MEDICAL MARIJUANA; CONTROLLED-TRIAL; PARALLEL-GROUP; DOUBLE-BLIND; EFFICACY; SAFETY; COMPLEMENTARY;

D O I：

10.1007/s11940-015-0385-y

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Several randomized trials have demonstrated potential benefit of cannabis derivatives in the symptomatic treatment of multiple sclerosis (MS) patients. These provide class 1 and 2 evidence for cannabinoid product use for spasticity and pain in these patients. The precise best ratio or doses are not yet clear. The safety and potential long-term effects of these products on cognitive function in people with MS have not been evaluated. Since short-term memory and processing speed can be significantly impaired in many people with MS, the concern of potential cognitive impairment related to cannabis products needs consideration in clinical care and should be addressed in longer, prospective studies.

引用

页码：1 / 14

页数：14

共 43 条

[11] Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial [J].

Ellis, Ronald J. ;

Toperoff, Will ;

Vaida, Florin ;

van den Brande, Geoffrey ;

Gonzales, James ;

Gouaux, Ben ;

Bentley, Heather ;

Atkinson, J. Hampton .

NEUROPSYCHOPHARMACOLOGY, 2009, 34 (03) :672-680

[12] Should doctors prescribe cannabinoids? [J].

Farrell, Michael ;

Buchbinder, Rachelle ;

Hall, Wayne .

BMJ-BRITISH MEDICAL JOURNAL, 2014, 348

[13]

Fife Terry D, 2015, Neurol Clin Pract, V5, P344

[14] Nabiximols (THC/CBD Oromucosal Spray, Sativex®) in Clinical Practice - Results of a Multicenter, Non-Interventional Study (MOVE 2) in Patients with Multiple Sclerosis Spasticity [J].

Flachenecker, Peter ;

Henze, Thomas ;

Zettl, Uwe K. .

EUROPEAN NEUROLOGY, 2014, 71 (5-6) :271-279

[15] SHORT-TERM EFFECTS OF SMOKING MARIJUANA ON BALANCE IN PATIENTS WITH MULTIPLE-SCLEROSIS AND NORMAL VOLUNTEERS [J].

GREENBERG, HS ;

WERNESS, SAS ;

PUGH, JE ;

ANDRUS, RO ;

ANDERSON, DJ ;

DOMINO, EF .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (03) :324-328

[16] Measures of Adult Pain Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP) [J].

Hawker, Gillian A. ;

Mian, Samra ;

Kendzerska, Tetyana ;

French, Melissa .

ARTHRITIS CARE & RESEARCH, 2011, 63 :S240-S252

[17] Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems A Clinical Review [J].

Hill, Kevin P. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (24) :2474-2483

[18] Safety, tolerability, and efficacy of orally administered cannabinoids in MS [J].

Killestein, J ;

Hoogervorst, ELJ ;

Reif, M ;

Kalkers, NF ;

van Loenen, AC ;

Staats, PGM ;

Gorter, RW ;

Uitdehaag, BMJ ;

Polman, CH .

NEUROLOGY, 2002, 58 (09) :1404-1407

[19] Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders Report of the Guideline Development Subcommittee of the American Academy of Neurology [J].

Koppel, Barbara S. ;

Brust, John C. M. ;

Fife, Terry ;

Bronstein, Jeff ;

Youssof, Sarah ;

Gronseth, Gary ;

Gloss, David .

NEUROLOGY, 2014, 82 (17) :1556-1563

[20] Endocannabinoids: A unique opportunity to develop multitarget analgesics [J].

Maione, Sabatino ;

Costa, Barbara ;

Di Marzo, Vincenzo .

PAIN, 2013, 154 :S87-S93

← 1 2 3 4 5 →